Mar 16, 2009 - Spectrum Pharmaceuticals announced today the closing of the transaction whereby Spectrum Pharmaceuticals acquired 100% control of RIT Oncology, LLC™, to commercialize ZEVALIN ([90Y]-ibritumomab tiuxetan) in the US. In connection with the closing, Spectrum Pharmaceuticals will pay its former partner a total of $16.5 million, which is subject to further adjustments based on outstanding liabilities and obligations.
The details can be read here.
No comments:
Post a Comment